Pharmacology/Pharmaceutical Industry
Consensus statement: Preoperative management of opioid and nonopioid analgesics
21 Feb, 2021 | 21:57h | UTC
RCT: Five oral analgesics (including opioids) are equally effective for the treatment of acute musculoskeletal extremity pain in the emergency department
21 Feb, 2021 | 21:39h | UTCA Randomized Trial Comparing the Efficacy of Five Oral Analgesics for Treatment of Acute Musculoskeletal Extremity Pain in the Emergency Department – Annals of Emergency Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Hot off the Press: A Randomized Trial Comparing the Efficacy of
Five Oral Analgesics for Treatment of Acute
Musculoskeletal Extremity Pain in the Emergency
Department https://t.co/qfUNn2TgZM @benjaminbwf pic.twitter.com/BzVM3W5F0L— AnnalsofEM (@AnnalsofEM) December 30, 2020
Opinion – Is it time to delay second doses of coronavirus vaccines?
21 Feb, 2021 | 22:39h | UTCIs it time to delay second doses of coronavirus vaccines? – CNN
3-month interval between first and second dose of Oxford COVID-19 vaccine results in higher vaccine efficacy than 6-week interval
21 Feb, 2021 | 22:42h | UTC
Opinion – Delayed second dose of the BNT162b2 vaccine: innovation or misguided conjecture?
21 Feb, 2021 | 22:38h | UTCDelayed second dose of the BNT162b2 vaccine: innovation or misguided conjecture? – The Lancet
Study: One Pfizer/BioNTech shot gives 85% Covid protection
21 Feb, 2021 | 22:41h | UTCOne Pfizer/BioNTech shot gives 85% Covid protection – study – The Guardian
Original study: Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients – The Lancet
Commentary on Twitter
NEW Correspondence reports early findings from study of #Pfizer #vaccine in health-care workers in Israel, suggesting early reductions in #COVID19 infection and symptomatic rates following first dose. Read https://t.co/ONU8bS3Iwo pic.twitter.com/BDDvA7Juyb
— The Lancet (@TheLancet) February 19, 2021
Pfizer vaccine doesn’t need ultra-cold storage after all, company says
21 Feb, 2021 | 22:37h | UTCPfizer vaccine doesn’t need ultra-cold storage after all, company says – ARS Technica
News release: PFIZER AND BIONTECH SUBMIT COVID-19 VACCINE STABILITY DATA AT STANDARD FREEZER TEMPERATURE TO THE U.S. FDA
Commentary on Twitter
?Pfizer BioNTech announced submission of new data to the U.S. FDA demonstrating the stability of their COVID-19 vaccine when stored at -25°C to -15°C (-13°F to 5°F), temperatures more commonly found in pharmaceutical freezers and refrigerators?https://t.co/egFsSe4oBB
— Antibiotic Steward? Bassam Ghanem (@ABsteward) February 19, 2021
A single dose of the Pfizer–BioNTech vaccine is 92.6% effective in preventing Covid-19. Is delaying the second dose to get more people vaccinated an alternative?
19 Feb, 2021 | 02:59h | UTCSafety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine – New England Journal of Medicine
Commentary: Researchers urge delaying Pfizer vaccine’s second dose as first highly effective – Reuters
Covid-19: In vitro studies show Pfizer-BioNTech and Moderna vaccines produce fewer antibodies against South African variant
19 Feb, 2021 | 03:01h | UTCCommentaries: Expert reaction to two NEJM Correspondence articles on in vitro studies of the Pfizer-BioNTech and Moderna vaccines and different variants/mutations including mutations on the South Africa variant – Science Media Centre AND Lab studies suggest Pfizer, Moderna vaccines can protect against coronavirus variant – CNN AND Pfizer and Moderna vaccines have reduced effectiveness against South African variant, newly published studies show – The Washington Post AND Pfizer, Moderna vaccines less effective against South African COVID variant – MedicalXpress
Commentary on Twitter
New reports @NEJM today confirming some immune evasion of the B.1.351 variant (identified in South Africa) to both the mRNA vaccines, in vitro data @BioNTech_Group/@Pfizer and @moderna_tx. Less vaccine efficacy vs B.1.351 has been confirmed in clinical trials for 3 vaccines pic.twitter.com/2N7eKDllso
— Eric Topol (@EricTopol) February 17, 2021
What does 95% COVID-19 vaccine efficacy really mean?
19 Feb, 2021 | 02:58h | UTCWhat does 95% COVID-19 vaccine efficacy really mean? – The Lancet Infectious Diseases
Related: Pfizer vaccine: what an ‘efficacy rate above 90%’ really means – The Conversation
Fauci: There’s evidence COVID-19 vaccines don’t just protect you — they may stop you from spreading the virus to others, too
19 Feb, 2021 | 02:46h | UTCRelated: [Preprint] Covid-19 vaccination associated with reduced viral load, may reduce transmission (study and commentary)
The price of success—how to evaluate Covid-19 vaccines when they’re available outside of clinical trials
19 Feb, 2021 | 02:43h | UTC
M-A: Not enough evidence there are individual differences in response to antidepressants
19 Feb, 2021 | 02:15h | UTCIndividual Differences in Response to Antidepressants: A Meta-analysis of Placebo-Controlled Randomized Clinical Trials – JAMA Psychiatry (free for a limited period)
Editorial: New Directions in Research on Heterogeneity of Treatment Effects for Major Depression (free for a limited period)
Commentary: Antidepressants for MDD: Time to Rethink Personalized Therapy? – Physician’s Weekly
Related studies: What are the chances for personalised treatment with antidepressants? Detection of patient-by-treatment interaction with a variance ratio meta-analysis – BMJ Open AND Individual response to antidepressants for depression in adults-a meta-analysis and simulation study – PLOS One
Commentary on Twitter (thread – click for more)
1/ Treatment effect heterogeneity in antidepressant tx – a retracted paper by Maslej et al. was now re-published, with a complete reversal of the main-findings – no difference in variability in tx outcome bw antidepressant and placebo. https://t.co/ME5qawCQlL https://t.co/IgegV5kZpT
— Pfluft (@PloederlM) February 18, 2021
RCT: Treatment of uterine fibroid symptoms with Relugolix combination therapy
19 Feb, 2021 | 02:08h | UTC
RCT: Vitamin D3 does not improve outcomes in hospitalized patients with moderate to severe COVID-19
18 Feb, 2021 | 03:20h | UTCEditorial: Vitamin D3 to Treat COVID-19: Different Disease, Same Answer
In this RCT a single high dose of #vitaminD3 (100K IU) raised mean serum 25OH D levels but had no effect on hospital LOS (primary outcome), in-hospital mortality, ICU admission, or need for mechanical ventilation (secondary outcomes) https://t.co/eozVaYnb25
— JAMA (@JAMA_current) February 17, 2021
Clinical decisions: Delayed second dose vs. standard regimen for Covid-19 vaccination
18 Feb, 2021 | 03:17h | UTC
SR: Concomitant use of levothyroxine and proton pump inhibitors causes a significant increase in TSH concentration
18 Feb, 2021 | 02:48h | UTC
A small, randomized cross-over trial showed Ivabradine may be a useful medication for hyperadrenergic POTS (Postural orthostatic tachycardia syndrome)
18 Feb, 2021 | 02:56h | UTCRandomized Trial of Ivabradine in Patients With Hyperadrenergic Postural Orthostatic Tachycardia Syndrome – Journal of the American Academy of Cardiology (link to abstract – $ for full-text)
Commentaries: Existing heart failure drug may treat potential COVID-19 long-hauler symptom, study suggests – University of California – San Diego AND Randomized Trial of Ivabradine in Patients With Hyperadrenergic Postural Orthostatic Tachycardia Syndrome – Ivabradine in POTS – American College of Cardiology
Commentary on Twitter
Our study showing ivabradine's benefit for POTS patients is out @JACCJournals. Also has implications for post-COVID 19 POTS (part of long haulers syndrome). Congrats to my co-first author/mentee @AdenaZadourian and the rest of my research team. @Dysautonomia @NIH @UCSDHealth pic.twitter.com/KGtzFh9CnT
— Pam R. Taub, MD (@PamTaubMD) February 15, 2021
M-A: Preventable medication harm across health care settings
18 Feb, 2021 | 02:43h | UTCCommentary: Preventable medication harm across health care settings: a systematic review and meta-analysis – PSNet
RCT: Avacopan for the treatment of ANCA-associated vasculitis
18 Feb, 2021 | 02:50h | UTCAvacopan for the Treatment of ANCA-Associated Vasculitis – New England Journal of Medicine (link to abstract – $ for full-text)
RCT: Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%
18 Feb, 2021 | 02:34h | UTC
Commentary on Twitter
Phase 3 trial suggests #cemiplimab could be used as new first-line monotherapy option for patients with advanced non-small-cell #lungcancer with PD-L1 of at least 50%—it improved overall & progression-free survival compared with chemotherapy. Read https://t.co/O06Of6wx07 pic.twitter.com/KtQ24lEoR5
— The Lancet (@TheLancet) February 17, 2021
How effective is magnesium in for the treatment of migraine?
16 Feb, 2021 | 01:48h | UTCHow Effective is Magnesium in your MAGraine Cocktail? – Journal Feed
Original study: MAGraine: Magnesium compared to conventional therapy for treatment of migraines – American Journal of Emergency Medicine
Should you mix and match COVID-19 vaccines? Scientists are seeking answers
16 Feb, 2021 | 02:18h | UTCShould you mix and match COVID-19 vaccines? Scientists are seeking answers – Science (a few articles per month are free)
See also: Could mixing COVID vaccines boost immune response? – Nature
Escaping Catch-22 — Overcoming Covid Vaccine Hesitancy
16 Feb, 2021 | 02:12h | UTCEscaping Catch-22 — Overcoming Covid Vaccine Hesitancy – New England Journal of Medicine
Potential health and economic impacts of dexamethasone treatment for patients with COVID-19
16 Feb, 2021 | 02:10h | UTC
Commentary on Twitter
RCTs Save Live$
DEXA saves live$
Potential health&economic impacts of dexamethasone treatment for #COVID19 patients
The study estimate that between July & Dec 2020, for ??, ~12,000 lives could be saved & ~650,000 lives saved globally over the same time https://t.co/B7jVa5Xc0s pic.twitter.com/mI0wPVUj4C— Antibiotic Steward? Bassam Ghanem (@ABsteward) February 10, 2021